Pharmacy Management

Pharmacies can strategically invest in AI technologies to streamline operations and improve patient care while addressing cost challenges and maximizing return on investment in 2025.

By aligning the pharmacy revenue cycle with the 340B Drug Pricing Program, organizations can maximize revenue capture from medications while ensuring compliance with 340B requirements, leading to enhanced financial performance and improved care for underserved populations.

Key trends shaping the future of health-system pharmacy include advanced medication management to address supply chain challenges, digital transformation to enhance pharmacy operations, and strategies for compliance with evolving regulations, all of which will be central topics at the ASHP Midyear 2024 meeting.

Using multiple physicians or pharmacists can result in a lack of coordinated care, missed medication interactions, and overlooked contraindications.

Once relatively obscure, PBMs are now front and center in debates over drug pricing and access. Their future role will have profound implications not only for how medications are priced but also for how pharmacies conduct their operations.

PBM reforms and regulatory changes have reshaped the industry landscape.

Incorporating the teach-back method and providing patient handouts expand health knowledge.

Effectively educating patients about their medications and disease trajectory can improve adherence and outcomes.

Retail pharmacies benefit from the shift from a volume-centric model to a value-centric approach that focuses on enhancing patient care, reducing pharmacist burnout, and leveraging technology to improve efficiency and expand the scope of pharmacy services.

A projected shortage of trained staff in the years ahead demands looking beyond normal hiring channels.

The future of health care is one where pharmacists play a pivotal role, and the Annual Enrollment Period is the perfect opportunity to prove it.

It is valuable for pharmacists to understand exactly how price transparency data are sourced, what information can be found, antitrust concerns, and implications for the pharmaceutical industry.

Eligible patients can receive a 30-day supply of covered drugs and medical supplies that can be renewed every 30 days for as long as an Emergency Prescription Assistance Program (EPAP) is active.

Lowering prescription drug costs for patients, saving taxpayers money, helping small businesses level an anti-competitive playing field: all of this is at stake.

Pharmacists should be aware of workplace hazards involving sharps and, if necessary, initiate oPEP.

Federal court reviews standing to challenge to federal agency action.

Three of the largest pharmacy benefit managers ––Express Scripts, Optum, and Caremark––are listed in the suit.

Federal statutes and regulations outline the expectations

With the introduction of expensive drugs and associated challenges for hospital budgets, pharmacy leaders benefit from strategically managing financial, clinical, and regulatory factors for sustainable care delivery.

New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.

High-cost novel therapies challenge payers and patients, while biosimilars help balance affordability.

The request comes as increased scrutiny is levied toward pharmacy benefit managers for alleged unfair business practices.

In survivors of lymphoma with fragmented transition of care, preparedness and activation for the next phase of their survivorship was lacking.

Examples include reviewing antibiotic doses, identifying drug-drug interactions, and implementing fall prevention strategies.